Winship | Strategic Alliance Partners

Latest from Winship

Investigators Look to Enhance Outcomes for Unresectable ESCC With Chemoradiation Combination

March 10, 2022

Since most diagnoses of esophageal squamous cell carcinoma are made when the disease is in advanced stages, investigators have initiated studies to evaluate the efficacy of immunotherapy in earlier lines of therapy, including in combination with chemoradiotherapy.

Biomarkers Allow for Tailoring TNBC Treatments

March 05, 2022

Several factors aid treatment selection for patients with newly diagnosed metastatic triple-negative breast cancer, with upfront PD-L1 and BRCA testing being the most critical biomarkers to examine.

Frontline Nivolumab/Ipilimumab Improves OS in Advanced NSCLC, Irrespective of Mutational Status

December 10, 2021

The dual immunotherapy combination comprised of nivolumab and ipilimumab improved overall survival vs chemotherapy in patients with advanced non–small cell lung cancer, irrespective of KRAS, TP53, or STK11 mutational status, according to data from exploratory analyses of part 1 of the CheckMate-227 trial.

Addition of Veliparib to Frontline Chemo Misses OS End Point in Current Smokers With Advanced Squamous NSCLC

August 31, 2021

The addition of veliparib to platinum-based chemotherapy in the frontline treatment of current smokers with advanced squamous non–small cell lung cancer did not significantly improve overall survival, but the LP52 signature may identify a subset of patients who will derive benefit from the combination.

18F-Fluciclovine-PET/CT Plus Conventional Imaging Improves Survival With Radiotherapy in Prostate Cancer

May 14, 2021

The use of 18F-fluciclovine-PET/CT in guiding salvage treatment with radiotherapy after prostatectomy reduced the likelihood of biochemical recurrence or suboptimal response to treatment in patients with prostate cancer without evidence of extrapelvic disease with conventional imaging.